0000876661-19-000203.txt : 20190308
0000876661-19-000203.hdr.sgml : 20190308
20190308151740
ACCESSION NUMBER: 0000876661-19-000203
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20190308
DATE AS OF CHANGE: 20190308
EFFECTIVENESS DATE: 20190308
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Asterias Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001572552
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461047971
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36646
FILM NUMBER: 19668870
BUSINESS ADDRESS:
STREET 1: 6300 DUMBARTON CIRCLE
CITY: FREMONT
STATE: CA
ZIP: 94555
BUSINESS PHONE: 510-456-3805
MAIL ADDRESS:
STREET 1: 6300 DUMBARTON CIRCLE
CITY: FREMONT
STATE: CA
ZIP: 94555
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE AMERICAN LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5414
MAIL ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE MKT LLC
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE AMERICAN LLC
1572552
Asterias Biotherapeutics, Inc.
001-36646
230 Constitution Drive
Menlo Park
CA
CALIFORNIA
94025
(650) 433-2900
Series A Common Stock par value $0.0001 per share
17 CFR 240.12d2-2(a)(3)
Victoria Paper
Senior Analyst
2019-03-08
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 19, 2019, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on March 8, 2019 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Asterias Biotherapeutics Inc. and BioTime Inc. became effective before market open on March 8, 2019. Each share of Common Stock of Asterias Biotherapeutics Inc., Inc. was exchanged for 0.71 of a share of BioTime, Inc. Common Shares.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading before the open on March 8, 2019.